The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 70 years of age

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 717-722

  Mook, S ^a   Schmidt, M K ^a   Weigelt, B ^a   Kreike, B ^a   Eekhout, I ^a   van de Vijver, M J ^a   Glas, A M ^a   Floore, A ^a   Rutgers, E J T ^a   van t Veer, L J ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

70 Gene prognosis signature; Breast cancer; Postmenopausal

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN;

ACCURACY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

AGED; BREAST NEOPLASMS; CARCINOMA; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE ARRAY ANALYSIS;

EID: 77950862535     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp388     Document Type: Article

References (28)

1. Ries LAG, Melbert D, Krapcho M et al. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute 2008; http://seer cancer gov/csr/1975_2005/(28 November 2008, date last accessed), based on November 2007 SEER data submission, posted to the SEER web site, 2008.
2. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002; 76: 27-36.
3. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000; 92: 550-556.
4. Fisher B, Wickerham DL, Brown A, Redmond CK. Breast cancer estrogen and progesterone receptor values: their distribution, degree of concordance, and relation to number of positive axillary nodes. J Clin Oncol 1983; 1: 349-358.
5. Anders C, Hsu D, Broadwater G et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008; 26: 3324-3330.
6. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
7. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
8. van de Vijver MJ, He YD, van 't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
9. Buyse M, Loi S, van 't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-1192.
10. Mook S, Schmidt MK, Viale G et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009; 116(2): 295-302.
11. Bueno-de-Mesquita JM, Linn SC, Keijzer R et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 2009; 117(3): 483-495.
12. Glas AM, Floore A, Delahaye LJ et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006; 7: 278-287.
13. Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980-991.
14. Olivotto IA, Bajdik CD, Ravdin PM et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23: 2716-2725.
15. Demicheli R, Miceli R, Moliterni A et al. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol 2005; 16: 1449-1457.
16. Klein CA, Blankenstein TJ, Schmidt-Kittler O et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002; 360: 683-689.
17. Schmidt-Kittler O, Ragg T, Daskalakis A et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 2003; 100: 7737-7742.
18. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738-2746.
19. Wittner BS, Sgroi DC, Ryan PD et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 2008; 14: 2988-2993.
20. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
21. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679.
22. Esteva FJ, Sahin AA, Cristofanilli M et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 2005; 11: 3315-3319.
23. Foekens JA, Atkins D, Zhang Y et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006; 24: 1665-1671.
24. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
25. Mauriac L, Keshaviah A, Debled M et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007; 18: 859-867.
26. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
27. Bogaerts J, Cardoso F, Buyse M et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006; 3: 540-551.
28. Mook S, van 't Veer LJ, Rutgers EJ et al. Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics 2007; 4: 147-155.